Hillhurst develops technologies enabling the therapeutic use of low-dose carbon monoxide.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: San Diego
State: California
Zip:
Country: United States
Hillhurst has created technology that allows low-dose carbon monoxide to be used therapeutically (CO). Their medicines that arise target a protective cellular metabolic system of heme oxygenase, that is hypothesized to reduce inflammatory processes, prevent cell death, and stop hemoglobin polymerization in sickle cell disease. Despite overwhelming evidence of CO&s;s potential efficacy as a therapy, it has not been commercially feasible to dose carbon monoxide. The methods of administration that have been tried, such as breathing CO and CO bound to a carrier like co releasing molecules/CORMS and CO prodrugs, have significant drawbacks. These hurdles for inhaled co include caregiver inhalation exposure due to the need for pressurized co gas cylinders and imprecise dosing.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|